Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. Methods: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for ≥8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited (<30%) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. Results: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statinexposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1%, 5.3%, 1.8% vs 19.2%, 2.9%, 2.9%, respectively). Propensity score analysis did not alter the overall findings. Conclusions: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD remains controversial.
Abstract
Background/Aims: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. Methods: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for ≥8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited (<30%) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. Results: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statinexposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1%, 5.3%, 1.8% vs 19.2%, 2.9%, 2.9%, respectively). Propensity score analysis did not alter the overall findings. Conclusions: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD remains controversial.
참고문헌 (50)
- Karlén P, "Increased risk of cancer in ulcerative colitis : a populationbased cohort study", Am J Gastroenterol, 94, pp.1047~1052 (1999)
- Bernstein CN, "Cancer risk in patients with inflammatory bowel disease : a population-based study", Cancer, 91, pp.854~862 (2001)
- Ekbom A, "Ulcerative colitis and colorectal cancer : a population-based study", N Engl J Med, 323, pp.1228~1233 (1990)
- Gillen CD, "Ulcerative colitis and Crohn’s disease : a comparison of the colorectal cancer risk in extensive colitis", Gut, 35, pp.1590~1592 (1994)
- Lutgens MW, "Declining risk of colorectal cancer in inflammatory bowel disease : an updated meta-analysis of population-based cohort studies", Inflamm Bowel Dis, 19, pp.789~799 (2013)
- Brentnall TA, "Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis", Gastroenterology, 110, pp.331~338 (1996)
- Broomé U, "Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer", Semin Liver Dis, 26, pp.31~41 (2006)
- Soetikno RM, "Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis : a meta-analysis", Gastrointest Endosc, 56, pp.48~54 (2002)
- Gupta RB, "Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis : a cohort study", Gastroenterology, 133, pp.1099~1105 (2007)
- Rutter M, "Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis", Gastroenterology, 126, pp.451~459 (2004)
- Laine L, "SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease", Gastrointest Endosc, 81, pp.489~501 (2015)
- Wanders LK, "Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis : a meta-analysis", Clin Gastroenterol Hepatol, 12, pp.756~764 (2014)
- Odze RD, "Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis", Clin Gastroenterol Hepatol, 2, pp.534~541 (2004)
- Blonski W, "High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis", Scand J Gastroenterol, 43, pp.817~820 (2008)
- Bezzio C, "Chemoprevention of colorectal cancer in ulcerative colitis : digging deep in current evidence", Expert Rev Gastroenterol Hepatol, 11, pp.339~347 (2017)
- Ehrlich AC, "Chemoprevention of colorectal cancer in inflammatory bowel disease", Expert Rev Anticancer Ther, 17, pp.247~255 (2017)
- Bardou M, "Effect of statin therapy on colorectal cancer", Gut, 59, pp.1572~1585 (2010)
- Stanilov N, "High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma", Int J Colorectal Dis, 24, pp.151~157 (2009)
- Kim PJ, "Survivin and molecular pathogenesis of colorectal cancer", Lancet, 362, pp.205~209 (2003)
- Shen W, "Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo", J Exp Clin Cancer Res, 28, pp.81~ (2009)
- Wang CY, "In vivo evidence of duality effects for lovastatin in a nude mouse cancer model", Int J Cancer, 126, pp.578~582 (2010)
- Jang HJ, "Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation", Oncol Lett, 12, pp.250~256 (2016)
- Gauthaman K, "Comparative evaluation of the effects of statins on human stem and cancer cells in vitro", Reprod Biomed Online, 15, pp.566~581 (2007)
- Narisawa T, "Prevention of 1, 2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice", Carcinogenesis, 15, pp.2045~2048 (1994)
- Asakage M, "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor(pravastatin)inhibits endothelial cell proliferation dependent on G1 cell cycle arrest", Anticancer Drugs, 15, pp.625~632 (2004)
- Skaletz-Rorowski A, "Statin therapy and angiogenesis", Curr Opin Lipidol, 14, pp.599~603 (2003)
- Nübel T, "Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion", FASEB J, 18, pp.140~142 (2004)
- Cho SJ, "Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice", Int J Cancer, 123, pp.951~957 (2008)
- Graaf MR, "Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer", Cancer Treat Rev, 30, pp.609~641 (2004)
- Poynter JN, "Statins and the risk of colorectal cancer", N Engl J Med, 352, pp.2184~2192 (2005)
- Farwell WR, "The association between statins and cancer incidence in a veterans population", J Natl Cancer Inst, 100, pp.134~139 (2008)
- Hoffmeister M, "Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer : a population-based case-control study", Int J Cancer, 121, pp.1325~1330 (2007)
- Dale KM, "Statins and cancer risk : a meta-analysis", JAMA, 295, pp.74~80 (2006)
- Boudreau DM, "Cardiovascular medication use and risk for colorectal cancer", Cancer Epidemiol Biomarkers Prev, 17, pp.3076~3080 (2008)
- Vinogradova Y, "Risk of colorectal cancer in patients prescribed statins, nonsteroidal antiinflammatory drugs, and cyclooxygenase-2 inhibitors : nested case-control study", Gastroenterology, 133, pp.393~402 (2007)
- Yang YX, "Chronic statin therapy and the risk of colorectal cancer", Pharmacoepidemiol Drug Saf, 17, pp.869~876 (2008)
- Singh H, "Long-term use of statins and risk of colorectal cancer : a population-based study", Am J Gastroenterol, 104, pp.3015~3023 (2009)
- Ananthakrishnan AN, "Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 14, pp.973~979 (2016)
- Samadder NJ, "Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use", Cancer, 117, pp.1640~1648 (2011)
- Riddell RH, "Dysplasia in inflammatory bowel disease : standardized classification with provisional clinical applications", Hum Pathol, 14, pp.931~968 (1983)
- Fiel M, "Histologic grading of disease activity in chronic IBD : inter-and intra-observer variation among pathologists with different levels of experience", Mod Pathol, 16, pp.118A~ (2003)
- Bonovas S, "Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients", J Clin Oncol, 25, pp.3462~3468 (2007)
- Friis S, "Cancer risk among statin users : a population-based cohort study", Int J Cancer, 114, pp.643~647 (2005)
- Bertagnolli MM, "Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial", Cancer Prev Res(Phila), 3, pp.588~596 (2010)
- Jung YS, "Statin use and the risk of colorectal adenoma : a meta-analysis", J Gastroenterol Hepatol, 31, pp.1823~1830 (2016)
- Siddiqui AA, "The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps", Digestion, 79, pp.17~22 (2009)
- Wei JT, "Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas", Cancer Epidemiol Biomarkers Prev, 14, pp.1026~1027 (2005)
- Itzkowitz SH, "Diagnosis and management of dysplasia in patients with inflammatory bowel diseases", Gastroenterology, 126, pp.1634~1648 (2004)
- Nieminen U, "Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD : a case-control observational study based on registry data", Int J Cancer, 134, pp.189~196 (2014)
- Rubin DT, "Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis : a case-control study", Clin Gastroenterol Hepatol, 11, pp.1601~1608 (2013)